Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
10.04
-0.19 (-1.86%)
At close: Aug 21, 2026, 4:00 PM EDT
10.20
+0.16 (1.59%)
After-hours: Aug 21, 2026, 7:37 PM EDT

Cartesian Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1.482.838.9126110.7885.08
Revenue Growth
43.96%-92.81%49.64%-76.53%30.21%-
Cost of Revenue
68.3958.0344.9165.6672.3868.74
Gross Profit
-66.91-55.24-5.99-39.6638.416.34
Selling, General & Admin
31.7531.4729.5334.7523.8620.94
Operating Expenses
31.7531.4729.5334.7523.8620.94
Operating Income
-98.66-86.71-35.52-74.4114.54-4.6
Interest Expense
-0.85---2.83-3.03-2.84
Interest & Investment Income
4.956.587.394.962.070.04
Currency Exchange Gain (Loss)
---0.04-0.02-
Other Non Operating Income (Expenses)
-3.223.69-3.73-136.1621.21-2.32
EBT Excluding Unusual Items
-97.78-76.44-31.86-208.434.77-9.72
Merger & Restructuring Charges
---0.8-11.3--
Gain (Loss) on Sale of Investments
-2-2----
Asset Writedown
-56.7-56.7-7.58-0.71--
Other Unusual Items
-4.6-4.35-36.9-18.3--
Pretax Income
-161.08-139.5-77.14-238.7134.77-9.72
Income Tax Expense
-9.19-9.190.29-19-0.6115.97
Net Income
-151.89-130.3-77.42-219.7135.38-25.69
Preferred Dividends & Other Adjustments
---37.55--
Net Income to Common
-151.89-130.3-77.42-257.2635.38-25.69
Net Income Growth
------
Shares Outstanding (Basic)
272617554
Shares Outstanding (Diluted)
272617554
Shares Change
9.55%49.63%235.72%6.33%27.59%-
EPS (Basic)
-5.61-5.02-4.48-49.767.33-6.74
EPS (Diluted)
-5.61-5.02-4.48-49.762.98-6.74
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-78.61-79.4-32.77-51.37-32.83-61.47
Free Cash Flow Per Share
-2.90-3.06-1.89-9.94-6.75-16.13
Gross Margin
---15.40%-152.50%34.66%19.21%
Operating Margin
-6679.69%-3099.93%-91.27%-286.13%13.12%-5.40%
Profit Margin
-10283.75%-4658.63%-198.97%-989.31%31.94%-30.19%
Free Cash Flow Margin
-5322.41%-2838.58%-84.21%-197.53%-29.64%-72.25%
EBITDA
-96.05-83.75-34.37-73.5615.83-3.35
EBITDA Margin
---88.32%-282.89%14.29%-3.93%
D&A For EBITDA
2.612.961.150.841.291.25
EBIT
-98.66-86.71-35.52-74.4114.54-4.6
EBIT Margin
---91.27%-286.13%13.12%-5.40%
Revenue as Reported
1.482.838.9126--
SEC Filings: 10-K · 10-Q